Skip to main content

Advertisement

SpringerLink
Log in

Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma

  • Upper Gastrointestinal Cancers (JD Berlin, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Metastatic (and locally advanced) pancreatic adenocarcinoma (mPDA) represents a major challenge for the oncology community given the rising mortality burden from the disease and the preponderance of patients diagnosed with unresectable disease. Although systemic therapies have become more potent with the development of fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel as first-line treatments, the median overall survival for patients treated with either of these regimens remains just above 1 year. A significant need exists to build upon the effectiveness of first-line regimens, incorporate tolerable maintenance treatments, and add effective later-line options for patients with this disease. We believe every newly diagnosed mPDA patient should undergo next-generation sequencing (NGS) testing, preferably from tumor tissue, to assess for the presence of DNA damage repair (DDR) defects, microsatellite instability, and other possible actionable molecular alterations (such as neurotrophic tropomysin receptor kinase (NTRK) fusions, anaplastic lymphoma kinase (ALK) rearrangements, or human epidermal growth factor receptor 2 (HER2) amplification). Existing clinical data suggests that patients, whose tumors harbor DDR defects, benefit from treatment with platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors. Preclinically, inhibitors of other critical players in DDR such as ataxia-telangiectasia and Rad3 related (ATR), ataxia-telangiectasia mutated (ATM), DNA-dependent protein kinase (DNA-PK), and WEE1 have demonstrated promising anti-tumor activity in PDA cell lines and xenografts. How to move forward the preclinical promise of these newer DDR-targeting therapies into rational clinical trial combinations and sequence PARP inhibitors in relation to platinum chemotherapy remain areas of tremendous clinical research interest. We believe clinical trials should be considered early for mPDA patients, in all treatment lines, so that novel therapies may be added to the treatment armamentarium for patients with this disease. Beyond NGS testing from tumor tissue, we believe it is important to consider germline genetic testing for all patients diagnosed with PDA given recent data suggesting a much stronger hereditary component of the disease than previously understood, and the potential screening implications for family members.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–84.

    Article  CAS  Google Scholar 

  2. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz011.

  3. Ascieto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2018;5(2):187–94.

    Article  Google Scholar 

  4. Motzer R, Escudier B, McDermott D, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.

    Article  CAS  Google Scholar 

  5. Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27.

    Article  CAS  Google Scholar 

  6. Nghiem P, Bhatia S, Lipson E, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542–52.

    Article  CAS  Google Scholar 

  7. Reck M, Rodriguez-Abreu D, Robinson A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

    Article  CAS  Google Scholar 

  8. •• Le D, Durham J, Smith K, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;57(6349):409–13 A seminal article which suggested the predictive power of microsatellite instability-high tumor status, across tumor histology, to predict benefit from the checkpoint inhibitor pembrolizumab.

    Article  Google Scholar 

  9. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828–33.

    Article  CAS  Google Scholar 

  10. SEER Database 2019. https://seer.cancer.gov/statfacts/html/pancreas.html.

  11. •• Pishvaian M, Blais E, Brody J, et al. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: results from the Know Your Tumor (KYT) program. J Clin Oncol. 2019;37(4):S191 An important publication suggesting that DDR mutations are more prevalent in PDA than previously thought and furthermore, that DDR mutations in tumors predict sensitivity to platinum chemotherapy.

    Article  Google Scholar 

  12. Heeke A, Pishvaian M, Lynce F, et al. Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis Oncol. 2018. https://doi.org/10.1200/PO.17.00286.

  13. Dreyer S, Paulus-Hock V, Upstill-Goddard R, et al. Defining DNA damage repair deficiency and replication stress in pancreatic cancer. J Clin Oncol. 2019;37(4):S285.

    Article  Google Scholar 

  14. Schroff R, Hendifar A, McWilliams R, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. J Prescis Oncol. 2018. https://doi.org/10.1200/PO.17.00316.

  15. •• Golan T, Varadhachary G, Sela T, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018;36(4):S297 An important study which sought to expand the role of PARP inhibitors to PDA patients beyond those with germline BRCA mutations. Preliminary results from this study suggest that PARP inhibitors have a role in PDA tumors with somatic mutations in other DDR genes.

    Article  Google Scholar 

  16. •• Reiss Binder K, Mick R, O’Hara M, et al. CT234 - a phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. Cancer Discov. 2019. https://doi.org/10.1158/2159-8290.CD-NB2019-043 An important study which suggested the biggest benefit of PARP inhibitors in mPDA patients may be in the platinum chemotherapy sensitive setting. The study also included patients beyond those with just germline BRCA mutations.

  17. Perkhofer L, Illing A, Gout J, et al. Precision medicine meets the DNA damage response in pancreatic cancer. Oncoscience. 2018;5(1–2):6–8.

    Article  Google Scholar 

  18. Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17(8):1670–82.

    Article  CAS  Google Scholar 

  19. Estrada-Bernal A, Chatterjee M, Hague SJ, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015;14(23):3713–24.

    Article  CAS  Google Scholar 

  20. Kaufman B, Shapira-Frommer R, Schmutzler R, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50.

    Article  CAS  Google Scholar 

  21. Hopkins T, Ainsworth W, Ellis P, et al. PARP1 Trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol Cancer Res. 2019. https://doi.org/10.1158/1541-7786.MCR-18-0138.

  22. Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018;89:19–26.

    Article  CAS  Google Scholar 

  23. •• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1903387 A practice-changing study which demonstrated the benefit of PARP inhibitors in the platinum sensitive maintenance setting for germline BRCA mutant mPDA patients in a randomized clinical trial. This study garnered olaparib an FDA indication for maintenance therapy.

  24. • Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Eng J Med. 2018;379:2495–505 An important paper describing the activity of PARP inhibitors in ovarian cancer. The activity of olaparib in this study should be contrasted with the activity of the agent in pancreatic adenocarcinoma.

    Article  CAS  Google Scholar 

  25. Litton J, Rugo H, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

    Article  CAS  Google Scholar 

  26. Yarchoan M, Myzak MC, Johnson BA, et al. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget. 2017;8(27):44073–81.

    Article  Google Scholar 

  27. O’Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018;124(7):1374–82.

    Article  Google Scholar 

  28. •• O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase ii trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.19.02931 An important study demonstrating the viability of gemcitabine plus cisplatin in PDA patients with germline deficits in BRCA and PALB2. This study also suggested that though veliparib increased RR when combined with gemcitabine plus cisplatin in patients, it did not improve survival outcomes.

  29. Pishvaian M, Wang H, Parenti S, et al. A phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients with metastatic pancreatic cancer (mPDAC). J Clin Oncol. 2019;37(15):S4015.

    Article  Google Scholar 

  30. • Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 5(9):a012716 A review which highlights the critical stimuli which trigger ATR and ATM along with the mechanisms and targets of the DDR-coordinating kinases.

  31. Dreyer S, Paulus-Hock V, Lampraki EM, et al. Defining DDR defectiveness in pancreatic cancer. J Clin Oncol. 2017;35(suppl;abstr 4115).

  32. Morton J, Timpson P, Karim S, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(1):246–51.

    Article  CAS  Google Scholar 

  33. Lal S, Zarei M, Chand S, et al. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Sci Rep. 2016;6:33323.

    Article  CAS  Google Scholar 

  34. Burki T. AZD1775 plus chemoradiotherapy for pancreatic cancer. Lancet Oncol. 2019;20(9):e472.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology Oncology, Vanderbilt University Medical Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN, 37232, USA

    Satya Das MD & Dana Cardin MSCI, MD

Authors
  1. Satya Das MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dana Cardin MSCI, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satya Das MD.

Ethics declarations

Conflict of Interest

Satya Das and Dana Cardin declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Upper Gastrointestinal Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Das, S., Cardin, D. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. Curr. Treat. Options in Oncol. 21, 62 (2020). https://doi.org/10.1007/s11864-020-00763-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00763-7

Keywords

Search

Navigation